L&K Biomed Ltd. (KOSDAQ:156100)
South Korea · Delayed Price · Currency is KRW 9,070.00
-280.00 (-2.99%)
At close: Mar 19, 2026
L&K Biomed Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 38,920 | 36,092 | 29,905 | 19,767 | 15,373 |
Other Revenue | - | - | -0 | -0 | -0 |
| 38,920 | 36,092 | 29,905 | 19,767 | 15,373 | |
Revenue Growth (YoY) | 7.84% | 20.69% | 51.28% | 28.59% | -20.58% |
Cost of Revenue | 6,898 | 5,950 | 4,227 | 4,975 | 8,019 |
Gross Profit | 32,022 | 30,142 | 25,678 | 14,792 | 7,354 |
Selling, General & Admin | 25,671 | 22,201 | 20,967 | 24,261 | 19,647 |
Research & Development | 2,462 | 2,053 | 1,329 | 1,369 | 1,358 |
Amortization of Goodwill & Intangibles | 60.3 | 14.9 | 86.26 | 46.82 | 146.24 |
Operating Expenses | 31,307 | 27,064 | 23,644 | 27,530 | 22,634 |
Operating Income | 715.12 | 3,078 | 2,034 | -12,738 | -15,280 |
Interest Expense | -3,073 | -2,681 | -2,002 | -2,206 | -1,380 |
Interest & Investment Income | 504.91 | 589.61 | 384.99 | 219.84 | 107.61 |
Earnings From Equity Investments | -200 | -300 | -1,172 | -1,199 | -556.16 |
Currency Exchange Gain (Loss) | -444.45 | 7,560 | 740.73 | 1,961 | 2,301 |
Other Non Operating Income (Expenses) | -14,766 | 1,621 | -330.56 | -2,027 | 4,630 |
EBT Excluding Unusual Items | -17,263 | 9,866 | -343.96 | -15,989 | -10,178 |
Gain (Loss) on Sale of Investments | 67.03 | 75.14 | 49.41 | - | 1,684 |
Gain (Loss) on Sale of Assets | 65.28 | 254.5 | 16.24 | -65.73 | 220.44 |
Asset Writedown | -15 | - | -16.8 | -243.71 | -623.87 |
Other Unusual Items | - | -380.94 | -6,173 | - | - |
Pretax Income | -17,146 | 9,815 | -6,468 | -16,299 | -8,897 |
Income Tax Expense | -353.85 | 663.59 | -1,229 | -65.76 | 4,749 |
Earnings From Continuing Operations | -16,792 | 9,151 | -5,239 | -16,233 | -13,646 |
Minority Interest in Earnings | 495.09 | 591.77 | 3,372 | 2,608 | 3,978 |
Net Income | -16,297 | 9,743 | -1,867 | -13,625 | -9,669 |
Net Income to Common | -16,297 | 9,743 | -1,867 | -13,625 | -9,669 |
Shares Outstanding (Basic) | 20 | 20 | 16 | 13 | 13 |
Shares Outstanding (Diluted) | 20 | 22 | 16 | 13 | 13 |
Shares Change (YoY) | -6.57% | 34.13% | 21.04% | 0.07% | 12.57% |
EPS (Basic) | -802.00 | 489.00 | -115.17 | -1017.14 | -722.29 |
EPS (Diluted) | -802.00 | 448.00 | -115.17 | -1017.14 | -722.29 |
Free Cash Flow | -16,870 | -8,015 | -3,417 | -6,684 | -10,501 |
Free Cash Flow Per Share | -830.21 | -368.54 | -210.77 | -498.99 | -784.49 |
Gross Margin | 82.28% | 83.52% | 85.87% | 74.83% | 47.84% |
Operating Margin | 1.84% | 8.53% | 6.80% | -64.44% | -99.40% |
Profit Margin | -41.87% | 27.00% | -6.24% | -68.93% | -62.90% |
Free Cash Flow Margin | -43.34% | -22.21% | -11.43% | -33.81% | -68.31% |
EBITDA | 3,497 | 5,650 | 4,347 | -10,436 | -13,555 |
EBITDA Margin | 8.99% | 15.65% | 14.54% | -52.80% | -88.18% |
D&A For EBITDA | 2,782 | 2,572 | 2,313 | 2,302 | 1,725 |
EBIT | 715.12 | 3,078 | 2,034 | -12,738 | -15,280 |
EBIT Margin | 1.84% | 8.53% | 6.80% | -64.44% | -99.40% |
Effective Tax Rate | - | 6.76% | - | - | - |
Advertising Expenses | 452.01 | 227.72 | 130.35 | 176.7 | 178.07 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.